On September 18, INSILICO rose 5.86% in regular trading, trading at HK$57.3/share, with turnover of HK$209 million. The stock extended gains following a series of positive catalysts accumulated over recent sessions.

On the news front, the company's core AI-driven drug candidate Rentosertib completed first patient dosing in the Phase III GENESIS-IPF-3 clinical trial at Peking Union Medical College Hospital on September 10, marking a historic milestone as the first generative AI-driven novel drug to enter Phase III globally. The trial plans to enroll 320 idiopathic pulmonary fibrosis patients over 52 weeks. Citi maintained a Buy rating with a target price of HK$85, naming INSILICO its top pick in the AI drug discovery sub-sector, citing the positive validation of its aging biology-led approach.

Additionally, Chairman and CEO Aleksandrs Zavoronkovs purchased 113,500 shares between September 4 and 7 using personal funds under a HK$16 million open-market buyback plan, raising his stake to approximately 8.02%. The company also completed a US$305 million zero-coupon convertible bond issuance, with 40% of proceeds earmarked for clinical trials and drug R&D.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)